Adaptive Immune Responses and Immunity to SARS-CoV-2

Area of Science:

• Immunology and Virology
• Infectious Disease Research
• Vaccinology

Background:

• The COVID-19 pandemic necessitated rapid application of immunological knowledge to SARS-CoV-2.
• Adaptive immune responses, involving T cells and B cells, are critical for host defense and immunological memory.
• SARS-CoV cellular immunity is known to persist long-term, suggesting similar potential for SARS-CoV-2.

Purpose of the Study:

• To interpret current research on SARS-CoV-2 adaptive immunity.
• To compare adaptive immune responses in naive, COVID-19 recovered, and vaccinated individuals.
• To analyze humoral responses in immunocompromised patients and the role of cellular immunity in breakthrough infections and variants.

Main Methods:

• Review and interpretation of recent SARS-CoV-2 research.
• Assessment of T cell memory via interferon-gamma levels upon viral peptide stimulation.
• Comparative analysis of adaptive immunity in different donor groups (naive, recovered, vaccinated).

Main Results:

• Individuals recovered from COVID-19 and those vaccinated with EMA-approved vaccines exhibit long-lasting cellular immunity.
• T cells are fundamental to humoral immune responses, influencing B cell activation and memory.
• IgA production by B cells is vital for mucosal immunity and potential nasal vaccine development.

Conclusions:

• Long-lasting cellular immunity is a significant outcome of both COVID-19 infection and vaccination.
• Understanding adaptive immunity is key to managing SARS-CoV-2, including breakthrough infections and variants.
• Cellular immunity plays a critical role in sustained host defense against SARS-CoV-2.